Gamaleya’s vaccine candidate is a viral vector vaccine based on human adenovirus — a common cold virus — fused with the spike protein of SARS-CoV-2 to stimulate an immune response.[10] The Gam-COVID-Vac vaccine candidate was developed by the same government labs that developed what is claimed "an effective against the Ebola virus, as well as a vaccine against the MERS virus".[11]